Filtered By:
Management: Health Insurance
Vaccination: Covid Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 247 results found since Jan 2013.
COVID-19 Vaccination Status Among Korean Pediatric Population With Comorbidities
J Korean Med Sci. 2023 Aug 14;38(32):e248. doi: 10.3346/jkms.2023.38.e248.ABSTRACTThe pediatric population with comorbidities is a high-risk group for severe coronavirus disease 2019 (COVID-19). As of January 2023, the COVID-19 vaccination rate for at least two doses among Korean children 5-11 years is low at 1.1%. We summarized the COVID-19 vaccination status for the pediatric population (5-17 years) with comorbidities through July 2022 using the National Health Insurance Service database. Pediatric patients with comorbidities had higher vaccination rates than the general pediatric population (2.4% vs. 1.1% in 5-11-year-o...
Source: J Korean Med Sci - August 15, 2023 Category: General Medicine Authors: Areum Shin Dong Wook Kim Young-Eun Kim Doo Ri Kim Jaehun Jung Yae-Jean Kim Source Type: research
Herpes zoster reactivation after mRNA and adenovirus-vectored coronavirus disease 2019 vaccination: Analysis of National Health Insurance Database
CONCLUSIONS: mRNA COVID-19 vaccination possibly increases the risk of herpes zoster reactivation, and thus close follow-up for herpes zoster reactivation is required.PMID:37549237 | DOI:10.1093/infdis/jiad297
Source: Herpes - August 7, 2023 Category: Infectious Diseases Authors: Jin Gu Yoon Young-Eun Kim Min Joo Choi Won Suk Choi Yu Bin Seo Jaehun Jung Hak-Jun Hyun Hye Seong Eliel Nham Ji Yun Noh Joon Young Song Woo Joo Kim Dong Wook Kim Hee Jin Cheong Source Type: research
Multiregional Population-Based Cohort Study for Evaluation of the Association Between Herpes Zoster and mRNA Vaccinations for Severe Acute Respiratory Syndrome Coronavirus-2: The VENUS Study
CONCLUSIONS: No increased risk of HZ was found after BNT162b2 vaccination in the overall study population. However, an increased risk was observed in the younger subgroup.PMID:37404955 | PMC:PMC10316690 | DOI:10.1093/ofid/ofad274
Source: Herpes - July 5, 2023 Category: Infectious Diseases Authors: Chieko Ishiguro Wataru Mimura Yukari Uemura Megumi Maeda Fumiko Murata Haruhisa Fukuda Source Type: research
Factors associated with receipt of mRNA-1273 vaccine at a United States national retail pharmacy during the COVID-19 pandemic
CONCLUSION: Over 80% of patients received their on-time second dose of mRNA-1273 vaccine per CDC recommendations. Patient demographics and community characteristics were associated with vaccine receipt and series completion. Novel approaches to facilitate series completion during a pandemic should be further studied.PMID:37296016 | PMC:PMC10172969 | DOI:10.1016/j.vaccine.2023.03.076
Source: Vaccine - June 9, 2023 Category: Allergy & Immunology Authors: Erin Roberts-McCarthy Philip O Buck Renae L Smith-Ray Nicolas Van de Velde Tanya Singh James Mansi Amy Shah Michael Taitel Source Type: research
The increasing age of respiratory syncytial virus-related hospitalisation during COVID-19 pandemic in Lyon was associated with reduced hospitalisation costs
CONCLUSIONS: The sharp reduction in costs of RSVH in infants aged < 3 months outweighed the modest increase in costs observed in the 3-24 months age group. Therefore, conferring a temporal protection through passive immunisation to infants aged < 3 months should have a major impact on RSVH costs even if it results in an increase of RSVH in older children infected later in life. Nevertheless, stakeholders should be aware of this potential increase of RSVH in older age groups presenting with a wider range of disease to avoid any bias in estimating the cost-effectiveness of passive immunisation strategies.PMID:37198017 ...
Source: Vaccine - May 17, 2023 Category: Allergy & Immunology Authors: Álvaro Roy St éphanie Polazzi Dominique Ploin Yves Gillet Etienne Javouhey Bruno Lina VRS study group in Lyon Anne-Florence Myard-Dury Sandrine Couray-Targe Antoine Duclos Jean-S ébastien Casalegno Source Type: research
Featured Health IT Jobs – Senior Epic Application Analyst
We like to regularly feature a healthcare IT job that might be of interest to readers. Today, we’re featuring the Senior Epic Application Analyst position that was recently posted on Healthcare IT Central. This position was posted by Yakima Valley Farm Workers Clinic and is located in Toppenish, Washington.
Here’s a description of the position:
YVFWC has a compulsory vaccination policy including the Covid-19 primary series, the organization does not mandate the Covid-19 booster although it is offered through our employee health department. Medical and religious exemptions to the primary series will be considered ...
Source: EMR and HIPAA - March 8, 2023 Category: Information Technology Authors: John Lynn Tags: Career and Jobs Healthcare IT Epic Jobs Featured Opportunities Health IT Careers Health IT Jobs Healthcare IT Jobs Job Seekers Senior Epic Application Analyst Yakima Valley Farm Workers Clinic Source Type: blogs
Retrieving Billions in Overpayments by CMS
This article focuses on the relatively young technologies that enable CMS to uncover overbillings, whether they be errors or fraud. The article is based on an interview with Kel Pults, chief clinical officer and vice president of MediQuant. A future article will explain how Medicare Advantage plans are trying to improving data collection and reporting, and how AI helps.
Challenges of Investigating Overpayments
Undeserved payments are needles lurking in the haystack of 135 million Americans enrolled in Medicare, Medicaid, and the Children’s Health Insurance Program (CHIP). But the needles pile up fast. Improper payments f...
Source: EMR and HIPAA - February 17, 2023 Category: Information Technology Authors: Andy Oram Tags: AI/Machine Learning Analytics/Big Data Health IT Company Healthcare IT Regulations Revenue Cycle Management #COVID19 CMS COVID Reimbursement Healthcare AI Healthcare Analytics Kel Pults MAOs Medicare Advantage MediQuant Overp Source Type: blogs
COVID-19 Bivalent Booster Vaccination Coverage and Intent to Receive Booster Vaccination Among Adolescents and Adults - United States, November-December 2022
MMWR Morb Mortal Wkly Rep. 2023 Feb 17;72(7):190-198. doi: 10.15585/mmwr.mm7207a5.ABSTRACTCOVID-19 vaccine booster doses are safe and maintain protection after receipt of a primary vaccination series and reduce the risk for serious COVID-19-related outcomes, including emergency department visits, hospitalization, and death (1,2). CDC recommended an updated (bivalent) booster for adolescents aged 12-17 years and adults aged ≥18 years on September 1, 2022 (3). The bivalent booster is formulated to protect against the Omicron BA.4 and BA.5 subvariants of SARS-CoV-2 as well as the original (ancestral) strain (3). Based on da...
Source: MMWR Morb Mortal Wkl... - February 16, 2023 Category: Epidemiology Authors: Peng-Jun Lu Tianyi Zhou Tammy A Santibanez Anurag Jain Carla L Black Anup Srivastav Mei-Chuan Hung Jennifer L Kriss Susanne Schorpp David Yankey Natalie Sterrett Hannah E Fast Hilda Razzaghi Laurie D Elam-Evans James A Singleton Source Type: research
